My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 532321 | NSE: ZYDUSLIFE | Pharmaceuticals & Drugs | Large Cap
1. Is Zydus Lifesciences Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Zydus Lifesciences Ltd is a good quality company.
2. Is Zydus Lifesciences Ltd undervalued or overvalued?
The key valuation ratios of Zydus Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Zydus Lifesciences Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Zydus Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |||
| ROCE % ⓘ | 14.2% | 18% | 25.7% | 14.8% | 14% | 11.8% | 7.4% | 12.4% | 10% | 8.4% | - | ||
| Value Creation Index ⓘ | 0.3 | 0.6 | 1.3 | 0.3 | 0.2 | 0.1 | -0.3 | 0.1 | -0.1 | -0.3 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 7,224 | 8,651 | 9,427 | 9,377 | 11,905 | 13,166 | 14,253 | 14,404 | 15,110 | 17,237 | 18,008 | ||
| YoY Gr. Rt. % | - | 19.8% | 9% | -0.5% | 27% | 10.6% | 8.3% | 1.1% | 4.9% | 14.1% | - | ||
| Adj EPS ⓘ | 7.7 | 11.3 | 18.9 | 14.4 | 17.4 | 18.2 | 11.9 | 22.5 | 20.1 | 17.4 | 25 | ||
| YoY Gr. Rt. % | - | 46.8% | 67.9% | -23.6% | 20.6% | 4.3% | -34.5% | 89.5% | -11% | -13.5% | - | ||
| BVPS (₹) ⓘ | 33.6 | 41.5 | 55.7 | 68 | 85.4 | 101.4 | 101.3 | 126.9 | 166 | 173.1 | 184 | ||
| Adj Net Profit ⓘ | 785 | 1,153 | 1,936 | 1,478 | 1,782 | 1,859 | 1,217 | 2,307 | 2,054 | 1,756 | 2,528 | ||
| Cash Flow from Ops. ⓘ | 903 | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,105 | 2,689 | - | ||
| Debt/CF from Ops. ⓘ | 3 | 2.7 | 1.3 | 4 | 5.9 | 6.2 | 2.7 | 1.4 | 2 | 0.4 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 10.2% | 7.7% | 6.5% | 14.1% | ||||||||
| Adj EPS ⓘ | 9.5% | -0.1% | 13.4% | -13.5% | ||||||||
| BVPSⓘ | 20% | 15.2% | 19.5% | 4.3% | ||||||||
| Share Price | 15.8% | 9.2% | 16.6% | 67.1% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | ||
| Return on Equity % ⓘ | 24.6 | 30 | 38.9 | 23.4 | 22.7 | 19.4 | 11.7 | 19.7 | 13.7 | 10.2 | 14 | |
| Op. Profit Mgn % ⓘ | 16.6 | 20.3 | 24.7 | 20.3 | 23.9 | 22.7 | 19.6 | 23.6 | 21 | 20.7 | 25.6 | |
| Net Profit Mgn % ⓘ | 11.3 | 13.7 | 20.4 | 15.7 | 14.7 | 14.1 | 8.5 | 16 | 14.2 | 10.4 | 14 | |
| Debt to Equity ⓘ | 0.8 | 0.6 | 0.4 | 0.8 | 0.6 | 0.8 | 0.8 | 0.4 | 0.3 | 0.1 | - | |
| Working Cap Days ⓘ | 155 | 153 | 158 | 178 | 185 | 213 | 210 | 103 | 107 | 102 | 0 | |
| Cash Conv. Cycle ⓘ | 66 | 61 | 53 | 63 | 80 | 101 | 103 | 10 | 18 | 20 | 0 | |
Net Profit is growing at healthy rate in last 3 years 13.42%
Sales growth is good in last 4 quarters at 21.00%
Return on Equity has declined versus last 3 years average to 14.00%
Sales growth has been subdued in last 3 years 6.54%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 19.6 | 25 |
| TTM Sales (₹ Cr.) | 9,455 | 18,008 |
| BVPS (₹.) ⓘ | 142.5 | 184 |
| Reserves (₹ Cr.) ⓘ | 14,319 | 18,528 |
| P/BV ⓘ | 4.18 | 3.24 |
| PE ⓘ | 30.47 | 23.88 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 350.30 / 668.50 |
| All Time Low / High (₹) | 5.53 / 673.70 |
| Market Cap (₹ Cr.) | 60,287 |
| Equity (₹ Cr.) | 101.2 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 41.7 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cadila Healthcare Limited, a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API) and human formulations. The company’s shares are listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.
The company’s initiatives in the areas of research and development span across the pharmaceuticals value chain, including New Chemical Entities (NCE), biologics, vaccines, specialty and complex generic formulations and API process development. The company has a global presence and sells its products in the United States, India, Europe and emerging markets including countries in Latin America, Asia Pacific region and Africa. The company has a pool of modern, cost efficient and regulatory compliant manufacturing facilities which ensures continuous supply of high quality products at the most competitive prices to its customers across the globe.
Business area of the company
The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. Innovation is the backbone of the company as it ensures business sustainability through continuous availability of new products for various businesses.
Business verticals / products
Awards
2008-09:
2009-10:
2010-11:
2011-12:
2012-13:
2013-14:
2014-15:
2015-16:
2016-17:
2017-18:
2018-19:
2019-20:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
